Catheter Precision, Inc. (VTAK)
AMEX AMEX Primary 
Catheter Precision, Inc. (NYSE American:VTAK) Reports First Purchase Order for LockeT in a New US Territory
FORT MILL, SC / ACCESSWIRE / September 4, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a MedTech company pioneering products in the growing field of cardiac electrophysiology, announced its first purchase order from a hospital in the greater Chicago area. As previously announced, the company has recently expanded their US sales and clinical team in preparation for the national product launch of LockeT which includes the Chicago region.
Catheter Precision, Inc. Announces Closing of $3.6 Million Underwritten Public Offering and Exercise of Overallotment Option
FORT MILL, SC / ACCESSWIRE / September 3, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company, today announced the closing of its previously announced public offering of 805,900 common stock units, including 458,623 common stock units issued upon exercise of the underwriters' over-allotment option, priced at a public offering price of $1.00 per unit, and 2,773,000 pre-funded warrant units, priced at a public offering price of $0.9999 per unit. Each common stock unit and pre-funded warrant unit consists of one share of common stock (or, in lieu of common stock, a pre-funded warrant to purchase one share of common stock at an exercise price of $0.0001), one warrant to purchase one share of common stock that expires on the six month anniversary of the date of issuance (a "Series H Warrant"), one warrant to purchase one share of common stock that expires on the eighteen month anniversary of the date of issuance (a "Series I Warrant"), and one warrant to purchase one share of common stock that expires on the five year anniversary of the date of issuance (a "Series J Warrant").
Catheter Precision, Inc. Announces Pricing of $3.1 Million Underwritten Public Offering
FORT MILL, SC / ACCESSWIRE / August 30, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company, today announced the pricing of its underwritten public offering of common stock units and pre-funded units for aggregate gross proceeds of approximately $3.1 million prior to deducting underwriting discounts and commissions and offering expenses. The equity offering is comprised of 347,277 common stock units, priced at a public offering price of $1.00 per unit, and 2,773,000 pre-funded warrant units, priced at a public offering price of $0.9999 per unit.
Catheter Precision, Inc. (NYSE American: VTAK) Reports Q2 2024 Highlights and Operational Performance Report
FORT MILL, SC / ACCESSWIRE / August 14, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a MedTech company pioneering products in the growing field of cardiac electrophysiology, including its VIVO™ and LockeT product(s), releases Q2 Financials and Operational Report. Operational highlights include the following: First commercial sales of LockeT in the US 14 new sales and clinical hires at various stages of training completion Larger number of US hospitals than projected have confirmed product interest and have scheduled evaluations 23 hospitals for LockeT 10 hospitals for VIVO VIVO product evaluation started at large volume center in Italy New LockeT publication in the Journal of Cardiovascular Electrophysiology Catheter Precision is attending the Kansas City Heart Rhythm Society Conference (KCHRS) in Kansas City August 17 and 18, 2024 Completion of the VIVO EU Registry in June 2024 2024 Second Quarter Financial Results are as follows: Total assets at June 30, 2024, were $26 million Total cash on position at June 30, 2024 was $16 thousand, and $330 thousand at August 12, 2024 Total revenues for the three and six months ended June 30, 2024, were $93 thousand and $175 thousand, respectively Shareholders' equity as of June 30, 2024, was $14.3 million Net loss for the three and six months ended June 30, 2024, was ($4.2) million and ($6.9) million, respectively LockeT sales for the three and six months ended June 30, 2024, were $38 thousand for both periods.
Catheter Precision, Inc. Announces Publication of LockeT Data in the Journal of Cardiovascular Electrophysiology
FORT MILL, SC / ACCESSWIRE / August 6, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based innovative medical device company, announced today the publication of its first LockeT study in the Journal of Cardiovascular Electrophysiology. The study titled, Feasibility, safety and efficacy of a novel external compression vascular closure device: The LockeT Study , was made available online on August 5, 2024.
Catheter Precision, Inc. Completes Enrollment of 75 Patients in LockeT-II Study
FORT MILL, SC / ACCESSWIRE / July 25, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based innovative medical device company, announced today that it has enrolled 75 patients in its Phase II LockeT Study, which is now expected to conclude in October 2024. As previously disclosed, the three phases of the LockeT studies began in 2023 and are intended to show the product's safety and benefits.
Catheter Precision, Inc. Announces Effectiveness of 1-for-10 Reverse Stock Split
FORT MILLS, SC / ACCESSWIRE / July 15, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based innovative medical device company, announced today that its previously announced 1-for-10 reverse stock split of its common stock became effective at 12:01 A.M. Eastern Time, on July 15, 2024.
Catheter Precision, Inc. Announces Receipt of LockeT Purchase Order for Eisenhower Medical Center, a Third California Hospital
FORT MILL, SC / ACCESSWIRE / June 17, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based innovative medical device company focused on electrophysiology products, announced an additional purchase order for its newest product, LockeT. As previously announced the company has recently expanded its US sales and clinical team in preparation for the national product launch of LockeT.
